FGF2 as a potential prognostic biomarker for proneural glioma patients

References

• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114: 97–109.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98–110.
   PubMed Web of Science ®Google Scholar
• Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006;1:97–117.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.
   PubMed Web of Science ®Google Scholar
• Stupp R, Tonn JC, Brada M, Pentheroudakis G, Group EGW. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v190–3.
   PubMed Web of Science ®Google Scholar
• Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol 2010;2:125–48.
   PubMedGoogle Scholar
• Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9(Suppl 5):S1–32; quiz S33.
   PubMedGoogle Scholar
• McNamara MG, Sahebjam S, Mason WP. Anaplastic oligodendroglioma: Advances and treatment options. Curr Treat Options Neurol 2013;15:289–301.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.
   PubMed Web of Science ®Google Scholar
• Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916–26.
   PubMed Web of Science ®Google Scholar
• Ponten F, Jirstrom K, Uhlen M. The Human Protein Atlas – a tool for pathology. J Pathol 2008;216:387–93.
   PubMed Web of Science ®Google Scholar
• Popova SN, Bergqvist M, Dimberg A, Edqvist PH, Ekman S, Hesselager G, et al. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology 2014;64:365–79.
   PubMed Web of Science ®Google Scholar
• Kampf C, Olsson I, Ryberg U, Sjostedt E, Ponten F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J Vis Exp 2012;(63). pii: 3620.
   PubMedGoogle Scholar
• Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM. Epidermal growth factor receptor: An independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 1996;34:809–15.
   PubMed Web of Science ®Google Scholar
• Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Saito T, Matsuura S, et al. Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. J Neurooncol 2006;77:273–7.
   PubMed Web of Science ®Google Scholar
• Polajeva J, Bergstrom T, Edqvist PH, Lundequist A, Sjosten A, Nilsson G, et al. Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5-dependent manner. Mol Oncol 2014;8:50–8.
   PubMed Web of Science ®Google Scholar
• Elsir T, Edqvist PH, Carlson J, Ribom D, Bergqvist M, Ekman S, et al. A study of embryonic stem cell-related proteins in human astrocytomas: Identification of Nanog as a predictor of survival. Int J Cancer 2014;134:1123–31.
   PubMed Web of Science ®Google Scholar
• Team TRDC. R: A language and environment for statistical computing. Vienna, Autria: R Foundation for Statistical Computing; 2009.
   Google Scholar
• Simon RM, Subramanian J, Li MC, Menezes S. Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. Brief Bioinform 2011;12:203–14.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344–50.
   PubMed Web of Science ®Google Scholar
• Brooks AN, Kilgour E, Smith PD. Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer. Clin Cancer Res 2012;18:1855–62.
   PubMed Web of Science ®Google Scholar
• Rades D, Seibold ND, Gebhard MP, Noack F, Schild SE. Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck. Strahlenther Onkol 2014;190:68–74.
   PubMed Web of Science ®Google Scholar
• Rades D, Setter C, Dahl O, Schild SE, Noack F. Fibroblast growth factor 2 – a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012;82:442–7.
   PubMed Web of Science ®Google Scholar
• Yiangou C, Gomm JJ, Coope RC, Law M, Luqmani YA, Shousha S, et al. Fibroblast growth factor 2 in breast cancer: Occurrence and prognostic significance. Br J Cancer 1997; 75:28–33.
   PubMed Web of Science ®Google Scholar
• Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 1992;76:792–8.
   PubMed Web of Science ®Google Scholar
• Parker BC, Engels M, Annala M, Zhang W. Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol 2014;232:4–15.
   PubMed Web of Science ®Google Scholar
• Auguste P, Gursel DB, Lemiere S, Reimers D, Cuevas P, Carceller F, et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and - independent mechanisms. Cancer Res 2001;61:1717–26.
   PubMed Web of Science ®Google Scholar
• Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231–5.
   PubMed Web of Science ®Google Scholar
• Lemieux SM, Hadden MK. Targeting the fibroblast growth factor receptors for the treatment of cancer. Anticancer Agents Med Chem 2013;13:748–61.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013;13:772–87.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 2012;3:84–97.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia- inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001;61:7992–8.
   PubMed Web of Science ®Google Scholar
• Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 2006;12: 6421–31.
   PubMed Web of Science ®Google Scholar
• Erpolat OP, Gocun PU, Akmansu M, Ozgun G, Akyol G. Hypoxia-related molecules HIF-1alpha, CA9, and osteopontin: Predictors of survival in patients with high-grade glioma. Strahlenther Onkol 2013;189: 147–54.
   PubMed Web of Science ®Google Scholar
• Jarvela S, Parkkila S, Bragge H, Kahkonen M, Parkkila AK, Soini Y, et al. Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 2008;8:1.
   PubMed Web of Science ®Google Scholar
• Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, et al. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 2006;12:473–7.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Perdiki M, Thymara I, Boviatsis E, Agrogiannis G, Kotsiakis X, et al. Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol 2007;38:629–38.
   PubMed Web of Science ®Google Scholar
• Sedlakova O, Svastova E, Takacova M, Kopacek J, Pastorek J, Pastorekova S. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Front Physiol 2014;4:400.
   PubMed Web of Science ®Google Scholar
• Krishnamachary B, Penet MF, Nimmagadda S, Mironchik Y, Raman V, Solaiyappan M, et al. Hypoxia regulates CD44 and its variant isoforms through HIF- 1alpha in triple negative breast cancer. PLoS One 2012; 7:e44078.
   PubMed Web of Science ®Google Scholar
• Ganat Y, Soni S, Chacon M, Schwartz ML, Vaccarino FM. Chronic hypoxia up-regulates fibroblast growth factor ligands in the perinatal brain and induces fibroblast growth factor-responsive radial glial cells in the sub-ependymal zone. Neuroscience 2002;112:977–91.
   PubMed Web of Science ®Google Scholar
• Brown JM. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies. Mol Med Today 2000;6:157–62.
   PubMedGoogle Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393–410.
   PubMed Web of Science ®Google Scholar